Drug intelligence / Profile preview

GM2814

Development stage: Preclinical
Lead developer: GreyMatter Pharma
Modality: Small Molecules

Overview

GM2814 is a drug candidate being developed by Grey Matter Pharma for the treatment of Mild Cognitive Impairment (MCI). The program utilizes a drug repurposing strategy, which involves identifying new therapeutic applications for existing, approved drugs. This approach aims to reduce the time and cost of drug development by leveraging established safety profiles. The specific identity of the repurposed molecule and its biological target have not been publicly disclosed by the company.

Beyond the preview

Go deeper on GM2814.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM2814.

Explore the full profile